Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 87.54 Billion KRW | 9.9% |
| 2022 | 79.65 Billion KRW | 13.58% |
| 2021 | 70.13 Billion KRW | 3.73% |
| 2020 | 67.61 Billion KRW | -9.5% |
| 2019 | 74.71 Billion KRW | -6.47% |
| 2018 | 79.87 Billion KRW | 9.49% |
| 2017 | 72.95 Billion KRW | 7.68% |
| 2016 | 67.75 Billion KRW | 13.76% |
| 2015 | 59.55 Billion KRW | 12.63% |
| 2014 | 52.87 Billion KRW | 10.71% |
| 2013 | 47.76 Billion KRW | -17.87% |
| 2012 | 58.15 Billion KRW | 21.79% |
| 2011 | 47.74 Billion KRW | -28.26% |
| 2010 | 66.56 Billion KRW | 12.66% |
| 2009 | 59.07 Billion KRW | 3.54% |
| 2008 | 57.05 Billion KRW | 4.96% |
| 2007 | 54.36 Billion KRW | 7.01% |
| 2006 | 50.8 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 39.41 Billion KRW | -56.59% |
| 2024 Q1 | 36.02 Billion KRW | 5.3% |
| 2024 Q2 | 39.37 Billion KRW | 9.32% |
| 2023 Q1 | 21.7 Billion KRW | -1.24% |
| 2023 FY | 87.54 Billion KRW | 9.9% |
| 2023 Q2 | 18.2 Billion KRW | -16.11% |
| 2023 Q3 | -22.42 Billion KRW | -223.15% |
| 2023 Q4 | 34.2 Billion KRW | 252.56% |
| 2022 Q2 | 19.31 Billion KRW | 8.47% |
| 2022 Q1 | 17.81 Billion KRW | 5.13% |
| 2022 FY | 79.65 Billion KRW | 13.58% |
| 2022 Q3 | 20.55 Billion KRW | 6.4% |
| 2022 Q4 | 21.97 Billion KRW | 6.91% |
| 2021 FY | 70.13 Billion KRW | 3.73% |
| 2021 Q1 | 19.02 Billion KRW | -1.33% |
| 2021 Q3 | 16.76 Billion KRW | -3.68% |
| 2021 Q2 | 17.4 Billion KRW | -8.53% |
| 2021 Q4 | 16.94 Billion KRW | 1.05% |
| 2020 Q1 | 17.24 Billion KRW | -15.36% |
| 2020 Q3 | 15.3 Billion KRW | -2.99% |
| 2020 Q4 | 19.28 Billion KRW | 26.0% |
| 2020 Q2 | 15.77 Billion KRW | -8.52% |
| 2020 FY | 67.61 Billion KRW | -9.5% |
| 2019 Q3 | 20.5 Billion KRW | 24.09% |
| 2019 Q4 | 20.37 Billion KRW | -0.6% |
| 2019 Q1 | 17.31 Billion KRW | -18.25% |
| 2019 FY | 74.71 Billion KRW | -6.47% |
| 2019 Q2 | 16.52 Billion KRW | -4.57% |
| 2018 FY | 79.87 Billion KRW | 9.49% |
| 2018 Q3 | 23.45 Billion KRW | 27.81% |
| 2018 Q4 | 21.17 Billion KRW | -9.72% |
| 2018 Q2 | 18.35 Billion KRW | 8.6% |
| 2018 Q1 | 16.89 Billion KRW | -17.04% |
| 2017 Q3 | 16.52 Billion KRW | -20.31% |
| 2017 Q1 | 15.32 Billion KRW | -11.91% |
| 2017 Q2 | 20.73 Billion KRW | 35.36% |
| 2017 FY | 72.95 Billion KRW | 7.68% |
| 2017 Q4 | 20.36 Billion KRW | 23.26% |
| 2016 Q3 | 18.89 Billion KRW | 21.96% |
| 2016 FY | 67.75 Billion KRW | 13.76% |
| 2016 Q2 | 15.49 Billion KRW | -3.04% |
| 2016 Q4 | 17.39 Billion KRW | -7.95% |
| 2016 Q1 | 15.97 Billion KRW | -9.72% |
| 2015 Q4 | 17.69 Billion KRW | 20.54% |
| 2015 Q2 | 14.84 Billion KRW | 20.38% |
| 2015 FY | 59.55 Billion KRW | 12.63% |
| 2015 Q3 | 14.68 Billion KRW | -1.1% |
| 2015 Q1 | 12.33 Billion KRW | -20.22% |
| 2014 Q4 | 15.45 Billion KRW | 19.6% |
| 2014 Q2 | 12.79 Billion KRW | 9.44% |
| 2014 Q1 | 11.69 Billion KRW | -4.53% |
| 2014 Q3 | 12.92 Billion KRW | 0.97% |
| 2014 FY | 52.87 Billion KRW | 10.71% |
| 2013 Q4 | 12.25 Billion KRW | 13.25% |
| 2013 FY | 47.76 Billion KRW | -17.87% |
| 2013 Q2 | 10.99 Billion KRW | -19.8% |
| 2013 Q1 | 13.7 Billion KRW | -7.21% |
| 2013 Q3 | 10.81 Billion KRW | -1.58% |
| 2012 Q2 | 14.95 Billion KRW | 3.33% |
| 2012 Q3 | 13.99 Billion KRW | -6.46% |
| 2012 FY | 58.15 Billion KRW | 21.79% |
| 2012 Q1 | 14.47 Billion KRW | 0.0% |
| 2012 Q4 | 14.76 Billion KRW | 5.56% |
| 2011 Q3 | 14.75 Billion KRW | -13.72% |
| 2011 Q2 | 17.1 Billion KRW | 6.75% |
| 2011 Q1 | 16.01 Billion KRW | -15.42% |
| 2011 FY | 47.74 Billion KRW | -28.26% |
| 2010 FY | 66.56 Billion KRW | 12.66% |
| 2010 Q3 | 15.64 Billion KRW | -1.98% |
| 2010 Q4 | 18.93 Billion KRW | 21.08% |
| 2010 Q2 | 15.95 Billion KRW | -1.95% |
| 2010 Q1 | 16.27 Billion KRW | 24.24% |
| 2009 Q4 | 13.1 Billion KRW | -15.85% |
| 2009 FY | 59.07 Billion KRW | 3.54% |
| 2009 Q1 | - KRW | -100.0% |
| 2009 Q2 | 14.13 Billion KRW | 0.0% |
| 2009 Q3 | 15.56 Billion KRW | 10.12% |
| 2008 FY | 57.05 Billion KRW | 4.96% |
| 2008 Q2 | 15.03 Billion KRW | 0.0% |
| 2008 Q3 | 13.42 Billion KRW | -10.72% |
| 2008 Q4 | 15.12 Billion KRW | 12.64% |
| 2008 Q1 | - KRW | -100.0% |
| 2007 Q2 | 13.19 Billion KRW | 0.0% |
| 2007 Q4 | 12.82 Billion KRW | -0.71% |
| 2007 FY | 54.36 Billion KRW | 7.01% |
| 2007 Q3 | 12.91 Billion KRW | -2.09% |
| 2006 FY | 50.8 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -85.259% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 70.623% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 68.56% |
| HANDOK Inc. | 153.76 Billion KRW | 43.069% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -26.481% |
| Yuhan Corporation | 489.94 Billion KRW | 82.132% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 71.481% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -109.483% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 85.672% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -21.614% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 49.731% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -118.565% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 6.424% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 23.694% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -85.259% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -106.118% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -16.646% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -49.276% |
| JW Holdings Corporation | 301.25 Billion KRW | 70.941% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 66.453% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 78.578% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 63.358% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 31.431% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -28.152% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -33.141% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 49.955% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -85.259% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 64.86% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 84.38% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 63.358% |
| Yuhan Corporation | 489.94 Billion KRW | 82.132% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 54.797% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -26.017% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -56.236% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 63.358% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 30.738% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 25.946% |
| CKD Bio Corp. | 25.19 Billion KRW | -247.448% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 60.566% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 46.981% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -31.806% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 31.431% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 75.039% |
| Boryung Corporation | 285.16 Billion KRW | 69.301% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 49.731% |
| JW Lifescience Corporation | 20.26 Billion KRW | -332.06% |